Investors aiming for above-average returns often turn to the practice of stock picking. Skillful choices in individual stocks can be a catalyst for substantial wealth growth.
In the latest session, Vanda Pharmaceuticals Inc (NASDAQ: VNDA) closed at $7.41 up 1.09% from its previous closing price of $7.33. In other words, the price has increased by $1.09 from its previous closing price. On the day, 1.21 million shares were traded. VNDA stock price reached its highest trading level at $7.44 during the session, while it also had its lowest trading level at $7.115.
Ratios:
For a deeper understanding of Vanda Pharmaceuticals Inc’s stock, let’s take a closer look at its various ratios. For the most recent quarter (mrq), Quick Ratio is recorded 3.10 and its Current Ratio is at 3.12. In the meantime, Its Debt-to-Equity ratio is 0.02 whereas as Long-Term Debt/Eq ratio is at 0.01.
Upgrades & Downgrades
In the most recent recommendation for this company, B. Riley Securities on November 05, 2025, initiated with a Buy rating and assigned the stock a target price of $11.
On October 31, 2024, H.C. Wainwright started tracking the stock assigning a Buy rating and target price of $18.
On July 11, 2024, Cantor Fitzgerald started tracking the stock assigning a Overweight rating and target price of $11.Cantor Fitzgerald initiated its Overweight rating on July 11, 2024, with a $11 target price.
Insider Transactions:
Additionally, insider trades can be beneficial to investors who want to learn what the management thinks about stock prices in the future. A recent insider transaction in this stock occurred on Aug 07 ’25 when Polymeropoulos Mihael Hristos bought 10,000 shares for $4.15 per share. The transaction valued at 41,500 led to the insider holds 2,335,731 shares of the business.
Mitchell Stephen Ray sold 7,000 shares of VNDA for $32,130 on Jun 13 ’25. The Director now owns 97,082 shares after completing the transaction at $4.59 per share. On Jun 13 ’25, another insider, Mitchell Stephen Ray, who serves as the Director of the company, bought 7,000 shares for $4.59 each.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, VNDA now has a Market Capitalization of 437906048 and an Enterprise Value of 155069024. For the stock, the TTM Price-to-Sale (P/S) ratio is 2.06 while its Price-to-Book (P/B) ratio in mrq is 0.94. Its current Enterprise Value per Revenue stands at 0.731 whereas that against EBITDA is -1.371.
Stock Price History:
The Beta on a monthly basis for VNDA is 0.62, which has changed by 0.67351604 over the last 52 weeks, in comparison to a change of 0.19226205 over the same period for the S&P500. Over the past 52 weeks, VNDA has reached a high of $9.60, while it has fallen to a 52-week low of $3.81. The 50-Day Moving Average of the stock is 25.78%, while the 200-Day Moving Average is calculated to be 49.94%.
Shares Statistics:
For the past three months, VNDA has traded an average of 1.62M shares per day and 4751960 over the past ten days. A total of 59.10M shares are outstanding, with a floating share count of 55.08M. Insiders hold about 6.79% of the company’s shares, while institutions hold 76.77% stake in the company. Shares short for VNDA as of 1767139200 were 2335804 with a Short Ratio of 1.44, compared to 1764288000 on 4642254. Therefore, it implies a Short% of Shares Outstanding of 2335804 and a Short% of Float of 4.099999700000001.
Earnings Estimates
. The current market rating for Vanda Pharmaceuticals Inc (VNDA) reflects the collective analysis of 4.0 analysts closely monitoring its performance.The consensus estimate for the next quarter is -$0.42, with high estimates of -$0.24 and low estimates of -$0.56.
Analysts are recommending an EPS of between -$1.77 and -$3.54 for the fiscal current year, implying an average EPS of -$2.67. EPS for the following year is -$1.45, with 4.0 analysts recommending between -$0.36 and -$2.42.
Revenue Estimates
A total of 4 analysts believe the company’s revenue will be $59.27M this quarter.It ranges from a high estimate of $62.5M to a low estimate of $56.9M. As of. The current estimate, Vanda Pharmaceuticals Inc’s year-ago sales were $53.19MFor the next quarter, 4 analysts are estimating revenue of $61.8M. There is a high estimate of $64M for the next quarter, whereas the lowest estimate is $57.4M.
A total of 4 analysts have provided revenue estimates for VNDA’s current fiscal year. The highest revenue estimate was $221.4M, while the lowest revenue estimate was $215.8M, resulting in an average revenue estimate of $218.17M. In the same quarter a year ago, actual revenue was $198.77MBased on 4 analysts’ estimates, the company’s revenue will be $271.27M in the next fiscal year. The high estimate is $298M and the low estimate is $236.4M.
